Article
Rapamycin enhances neurovascular, peripheral metabolic, and immune function in cognitively normal, middle-aged APOE4 Carriers: genotype-dependent effects compared to non-carriers
2025-03-19
Abstract excerpt
<title>Abstract</title> <p>Rapamycin, known for its anti-aging properties, shows promise as a preventive strategy for Alzheimer’s disease (AD) in APOE4 carriers—the highest-risk group for late-onset AD. Here we show that a 4-week open-label trial of low-dose Rapamycin (Sirolimus; 1 mg/day) significantly improved cerebral blood flow (CBF) relative to baseline in cognitively normal APOE4 carriers (E4(+)) aged 45–65...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- fdb7247f-9a30-5c36-8e10-fe939fef68e5
- DOI
- 10.21203/rs.3.rs-6214340/v1
